INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Teva Pharmaceut...
November 18 2016 - 11:45PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the Central
District of California on behalf of purchasers of Teva
Pharmaceutical Industries Limited (NYSE: TEVA) (“Teva” or the
“Company”) American Depositary Shares (“ADSs”) during the period
between February 10, 2015 and November 3, 2016, inclusive (the
“Class Period”). Investors who wish to become proactively involved
in the litigation have until January 5, 2017 to seek appointment as
lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from
investment in Teva ADSs during the Class Period. Members of the
Class will be represented by the lead plaintiff and counsel chosen
by the lead plaintiff. No class has yet been certified in the above
action.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that Teva was engaging
and/or had engaged in conduct that would result in an antitrust
investigation by the U.S. Department of Justice (“DOJ”) and the
State of Connecticut Office of the Attorney General, the DOJ
investigation and the underlying conduct could cause prosecutors to
file criminal charges for suspected price collusion, and that the
Company lacked effective internal controls over financial
reporting. According to the complaint, following an August 4, 2016
filing announcing that the Company had received a subpoena from the
DOJ and the State of Connecticut Office of the Attorney General
relating to marketing and pricing, and a November 3, 2016 article
revealing that prosecutors may file criminal charges, the value of
Teva shares declined significantly.
If you have suffered a loss in excess of $100,000 from
investment in Teva ADSs purchased on or after February 10, 2015 and
November 3, 2016 and held through the revelation of negative
information during and/or at the end of the Class Period and would
like to learn more about this lawsuit and your ability to
participate as a lead plaintiff, without cost or obligation to you,
please visit our website at
http://www.browerpiven.com/currentsecuritiescases.html. You may
also request more information by contacting Brower Piven either by
email at hoffman@browerpiven.com or by telephone at (410) 415-6616.
Brower Piven also encourages anyone with information regarding the
Company’s conduct during the period in question to contact the
firm, including whistleblowers, former employees, shareholders and
others.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161118005592/en/
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024